Monoclonal Antibody Therapies for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder

Considerable progress has been made in treatments for multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) over the last several decades. However, the present treatments do not show satisfactory efficacy or safety in a considerable proportion of patients, who experience relapse...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Woojun, Kim, Ho Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Neurological Association 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354979/
https://www.ncbi.nlm.nih.gov/pubmed/32657055
http://dx.doi.org/10.3988/jcn.2020.16.3.355

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354979/
https://www.ncbi.nlm.nih.gov/pubmed/32657055
http://dx.doi.org/10.3988/jcn.2020.16.3.355

Ejemplares similares